Chung Paul A, Dilling Daniel F
Division of Pulmonary and Critical Care, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.
Ann Transl Med. 2020 Mar;8(6):409. doi: 10.21037/atm.2019.12.117.
Lung transplantation is a viable option for those with end-stage lung disease which is evidenced by the continued increase in the number of lung transplantations worldwide. However, patients and clinicians are constantly faced with acute and chronic rejection, infectious complications, drug toxicities, and malignancies throughout the lifetime of the lung transplant recipient. Conventional maintenance immunosuppression therapy consisting of a calcineurin inhibitor (CNI), anti-metabolite, and corticosteroids have become the standard regimen but newer agents and modalities continue to be developed. Here we will review induction agents, maintenance immunosuppressives, adjunctive therapies and other strategies to improve long-term outcomes.
肺移植对于那些患有终末期肺病的患者来说是一种可行的选择，全球肺移植数量的持续增加证明了这一点。然而，在肺移植受者的整个生命周期中，患者和临床医生始终面临急性和慢性排斥反应、感染性并发症、药物毒性和恶性肿瘤等问题。由钙调神经磷酸酶抑制剂（CNI）、抗代谢药物和皮质类固醇组成的传统维持免疫抑制疗法已成为标准方案，但新的药物和治疗方式仍在不断研发。在此，我们将综述诱导剂、维持免疫抑制剂、辅助治疗以及其他改善长期预后的策略。
